SKAN Group AG
SIX:SKAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SKAN Group AG
Accrued Liabilities
SKAN Group AG
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SKAN Group AG
SIX:SKAN
|
Accrued Liabilities
CHf15.6m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Accrued Liabilities
CHf47.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Accrued Liabilities
CHf63.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Tecan Group AG
SIX:TECN
|
Accrued Liabilities
CHf97.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Accrued Liabilities
€16.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
SKAN Group AG
Glance View
SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.
See Also
What is SKAN Group AG's Accrued Liabilities?
Accrued Liabilities
15.6m
CHF
Based on the financial report for Dec 31, 2025, SKAN Group AG's Accrued Liabilities amounts to 15.6m CHF.
What is SKAN Group AG's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
42%
Over the last year, the Accrued Liabilities growth was 154%. The average annual Accrued Liabilities growth rates for SKAN Group AG have been 42% over the past three years .